UCB S.A.

Briviact (brivaracetam) is prescribed as an adjuvant treatment for partial onset seizures in adults, adolescents, and children with epilepsy starting at age 2 in Europe, with or without secondary generalization. Brivaracetam CV, also known as BRIVIACT, is prescribed in the United States to treat partial-onset seizures in patients aged one month and up.

As an adjuvant therapy for primary generalized tonic-clonic seizures in patients aged four and up, Vimpat (lacosamide) CV is recommended for the treatment of partial-onset seizures in patients aged 1 month and up.

In the United States, patients one month of age and older who have partial-onset seizures can be treated with Keppra (levetiracetam) as a supplemental therapy to treat myoclonic seizures in patients with juvenile myoclonic epilepsy aged 12 and up. In Europe, adults and adolescents with newly diagnosed epilepsy starting at age 16 who have partial onset seizures with or without secondary generalization can be treated with Keppra (levetiracetam) as a monotherapy.